Germans Trias i Pujol Hospital — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Germans Trias i Pujol Hospital appears in 68 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials68

Recruiting shown4

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Study of the Brain's Natural Cleaning System in Potential Organ Donors.NCT07682155 · lead sponsor · 2026-02-01

Impact of Nipple Reconstruction in Mastectomized Patients Using Cross-Linked Hyaluronic Acid Injection.NCT07008339 · lead sponsor · 2023-06-02

AI-based Echocardiography for Detection of Cardiac AmyloidosisNCT07529860 · lead sponsor · 2026-07-01

NOT_YET_RECRUITING

Program for the Promotion of Physical Exercise and Healthy Eating Among Population of Pakistani Origin With ObesityNCT07009054 · lead sponsor · 2024-03-03

Neuroinflammation, Affective and Cognitive Symptoms in Major Depression and PsoriasisNCT04423471 · lead sponsor · 2021-02-01

Atrial Amyloid May Influence Outcomes in Patients Undergoing Surgical Aortic Valve ReplacementNCT07105501 · lead sponsor · 2020-11-03

Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS DeviceNCT04753112 · lead sponsor · 2020-10-29

Efficacy and Safety of Non-resorbable Uveoscleral Implant Versus Absorbable Collagen Matrix in Non-perforating Deep SclerectomyNCT04586738 · lead sponsor · 2020-09-01

Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart FailureNCT03741972 · lead sponsor · 2018-12-21

Carbohydrates Distribution in Pregnancy StudyNCT03378908 · lead sponsor · 2018-02-01

Changes in Choroidal Thickness After Non Penetrating Deep SclerectomyNCT03160690 · lead sponsor · 2017-06-17

Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple SclerosisNCT02035514 · lead sponsor · 2013-12-01

Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in RelapseNCT01986998 · lead sponsor · 2013-10-01

Nutritional Status and Prognosis in Heart Failure.NCT01396824 · lead sponsor · 2011-06-01

Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir MonotherapyNCT01116817 · lead sponsor · 2010-08-01

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In Hiv-1-Infected Subjects With Loss Of Bone Mineral DensityNCT01153217 · lead sponsor · 2010-07-01

Drug Interactions Between Echinacea Purpurea and Darunavir/RitonavirNCT01046890 · lead sponsor · 2010-01-01

Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia SuppressionNCT01034917 · lead sponsor · 2009-12-01

Efficacy And Security Of Annual And Biennial Zoledronic Acid For Osteoporosis Treatment In An HIV-Infected Patients' CohortNCT00795483 · lead sponsor · 2009-11-01

Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIVNCT00995241 · lead sponsor · 2009-11-01

Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV SubjectsNCT00966329 · lead sponsor · 2009-10-01

Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-RegimensNCT00994344 · lead sponsor · 2009-10-01

Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed ProductNCT00773708 · lead sponsor · 2009-03-01

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/EmtricitabineNCT00808002 · lead sponsor · 2009-02-01

Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During RelapseNCT00753792 · lead sponsor · 2008-11-01

Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral TherapyNCT00718536 · lead sponsor · 2008-08-01

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in SpainNCT00685191 · lead sponsor · 2008-06-01

Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV PatientsNCT00661349 · lead sponsor · 2008-02-01

Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification StrategyNCT00611039 · lead sponsor · 2008-02-01

Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 HoursNCT00607958 · lead sponsor · 2007-12-01

Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral SuppressionNCT00554398 · lead sponsor · 2007-11-01

Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment RegimensNCT00470210 · lead sponsor · 2007-05-01

Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+NCT00552682 · lead sponsor · 2007-01-01

Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV PatientsNCT00355719 · lead sponsor · 2007-01-01

Modification of Doses of Efavirenz According to Its Blood Concentration in HIV PatientsNCT00299091 · lead sponsor · 2006-09-01

Influence of Atorvastatin on Viral Replication During Antiretroviral Treatment InterruptionNCT00355251 · lead sponsor · 2006-07-01

Saquinavir/Ritonavir in Single Therapy as Maintenance TreatmentNCT00379405 · lead sponsor · 2006-06-01

Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected PatientsNCT00287677 · lead sponsor · 2006-01-01

Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIVNCT00356486 · lead sponsor · 2005-10-01

Immuno-Virological Efficacy of Combination With Trizivir +Tenofovir in Multiresistant HIV PatientsNCT00356616 · lead sponsor · 2005-09-01

Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C PatientsNCT00166296 · lead sponsor · 2005-03-01

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIVNCT00307502 · lead sponsor · 2005-01-01

To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and TenofovirNCT00335192 · lead sponsor · 2005-01-01

Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once DailyNCT00314626 · lead sponsor · 2004-11-01

Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV PatientsNCT00318123 · lead sponsor · 2004-04-01

Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV PatientsNCT00335686 · lead sponsor · 2003-10-01

Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients CohortNCT00662077 · lead sponsor

Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)NCT07481175 · collaborator · 2026-04-13

Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)NCT06599918 · collaborator · 2024-04-23

Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1NCT07028385 · collaborator · 2025-09-22

SIRAKI 02 Posthoc Analysis.NCT06781294 · collaborator · 2024-10-01

ACTIVE_NOT_RECRUITING

Prevalence and Impact of Pertussis and RSV on Asthma Severity and ControlNCT06286007 · collaborator · 2023-12-21

Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral TreatmentNCT05780073 · collaborator · 2023-10-16

Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.NCT06434753 · collaborator · 2022-10-02

Bariatric Surgery in Patients With SchizophreniaNCT06043206 · collaborator · 2022-10-01

IMPACt of an Enhanced Screening Program on the Detection of Non-AIDS NEOplasms in HIV PatientsNCT04735445 · collaborator · 2019-11-11

Clinical Trial to Evaluate the Addition to an Antiretroviral Treatment of a ProbioticNCT03542786 · collaborator · 2017-12-18

iHIVARNA Clinical Trial in HIV Infected IndividualsNCT02888756 · collaborator · 2017-04-04

Respiratory Microbiome and COPD Exacerbations (RESMECOPD)NCT03432234 · collaborator · 2016-03-07

Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected IndividualsNCT02616874 · collaborator · 2016-02-01

Drugs studied in this sponsor's trials

19 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Germans Trias i Pujol Hospital as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

lopinavir / ritonavir3

placebo3

raltegravir3

efavirenz2

maraviroc2

nevirapine2

atazanavir1

dasatinib 70 MG1

lopinavir / ritonavir RxCUI 284640 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials placebo RxCUI 8375 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 3 trials raltegravir RxCUI 719872 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials efavirenz RxCUI 195085 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials maraviroc RxCUI 620216 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials nevirapine RxCUI 53654 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials atazanavir RxCUI 343047 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial dasatinib 70 MG RxCUI 643108 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial Echinacea preparation RxCUI 228041 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial escitalopram RxCUI 321988 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ibandronate RxCUI 115264 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial methylprednisolone RxCUI 6902 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial nelfinavir RxCUI 134527 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial niacinamide RxCUI 7405 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial romidepsin RxCUI 877510 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial sacubitril / valsartan Oral Tablet [Entresto] RxCUI 1656343 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial testosterone undecanoate RxCUI 37864 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial venetoclax RxCUI 1747556 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial zoledronic acid RxCUI 77655 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor47

collaborator21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.